KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)
Kidney International – 2025
Not funded by Travere
Search Results
Filter by:
Information type
Information type
×Therapeutic area
Therapeutic area
×Disease area
Disease area
×Product
Product
×Study/Registry
Study/Registry
×Study type
Study type
×Resource type
Resource type
×Filter by:
Information type
Information type
×Therapeutic area
Therapeutic area
×Disease area
Disease area
×Product
Product
×Study/Registry
Study/Registry
×Study type
Study type
×Sort by
Publications
Results50
Efficacy and Safety of ACE Inhibitor and Angiotensin Receptor Blocker Therapies in Primary Focal Segmental Glomerulosclerosis Treatment: A Systematic Review and Meta-Analysis
Kidney Medicine – 2022
Sparsentan Improves Glomerular Hemodynamics, Cell Functions, and Tissue Repair in a Mouse Model of FSGS
JCI Insight – 2024
Population-Level Risk Factors for Kidney Outcomes in IgA Nephropathy: The CURE-CKD Registry
Kidney Medicine – 2025
The Humanistic Burden of Focal Segmental Glomerulosclerosis on Patients and Care‑Partners in the United States
Quality of Life Research – 2025
Population Risk Predictors of Major Adverse Kidney Events Attributed to FSGS from the CURE-CKD Registry
BMC Nephrology – 2025
Congress materials
Results124
Patients With Focal Segmental Glomerulosclerosis (FSGS) Reach Proteinuria <0.7 g/g More Often With Sparsentan vs Irbesartan in DUPLEX: Implications for Kidney Failure Risk
American Society of Nephrology (ASN) Kidney Week – 2025
Patients With Focal Segmental Glomerulosclerosis (FSGS) Reach Proteinuria <0.7 g/g More Often With Sparsentan vs Irbesartan in DUPLEX: Implications for Kidney Failure Risk
American Society of Nephrology (ASN) Kidney Week – 2025
Sparsentan vs. Irbesartan in Pediatric Patients with Focal Segmental Glomerulosclerosis (FSGS) in the Phase 3 DUPLEX Trial
American Society of Nephrology (ASN) Kidney Week – 2025
Sparsentan vs. Irbesartan in Pediatric Patients with Focal Segmental Glomerulosclerosis (FSGS) in the Phase 3 DUPLEX Trial
American Society of Nephrology (ASN) Kidney Week – 2025
PROTECT Post Hoc Analysis: Efficacy of Sparsentan vs Irbesartan in Patients With IgA Nephropathy ≤12 mo vs >12 mo From Kidney Biopsy
American Society of Nephrology (ASN) Kidney Week – 2025
Impact of Histology on Efficacy of Sparsentan Therapy in IgA Nephropathy: Central Biopsy Review of Patients in the PROTECT Trial
American Society of Nephrology (ASN) Kidney Week – 2025
Events
Results17
Past
September 14, 2025
GlomCon & Travere: The Dual Impact of Sparsentan on Inflammation and Proteinuria in IgAN
Past
November 6–9, 2025
American Society of Nephrology (ASN) Kidney Week 2025
Past
September 22–25, 2025 – O’ahu, HI, USA
GlomCon Hawaii 2025
Past
September 21–24, 2025 – Charleston, South Carolina
19th International Conference on Endothelin (ET-19)
Past
September 17–20, 2025 – Prague, Czech Republic
International Symposium on IgA Nephropathy (IIgANN)
Past
June 10–13, 2025 – Hamburg, Germany
15th International Podocyte Conference and 2025 ISGD Meeting
Downloadable resources
Results7
KDIGO 2025 Infographic
FILSPARI US PI
FSGS Mechanism of Action
Travere Infographic-Overview of data on concomitant use of sparsentan and SGLT2i in IgA nephropathy
Travere Therapeutics – PROTECT 2-year findings Infographic Dec 2024
Kohan Infographic
Abstracts
Results48
Pivotal Results of the Phase 3 PROTECT Trial of Sparsentan (SPAR) vs Irbesartan (IRB) in Patients (Pts) With Immunoglobulin A Nephropathy (IgAN)
Concomitant Sparsentan and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is) in Patients With IgA Nephropathy (IgAN) in the PROTECT Open-Label Extension (OLE)
Sparsentan as First-Line Treatment of Incident Patients With IgA Nephropathy: Preliminary Findings From the SPARTAN Trial
Sparsentan Receptor Occupancy Modeling, Clinical Actions, and Safety Visual Abstract
Pivotal Results of the Phase 3 PROTECT Trial of Sparsentan (SPAR) vs Irbesartan (IRB) in Patients (Pts) With Immunoglobulin A Nephropathy (IgAN)
Sparsentan (SPAR) vs Irbesartan (IRB) in Patients With Focal Segmental Glomerulosclerosis (FSGS): Results From the Phase 3 DUPLEX Trial